Ashland (ASH) Q2 2026 earnings review
Sales Finally Grow, But Operational Missteps Crush Margins
Ashland achieved a reversing trend in the top line, posting its first positive YoY sales growth (+1%) in over a year. However, the volume recovery completely bypassed the bottom line. Adjusted EBITDA fell 9% to $98M, and Net Income plunged 48% to $16M. The culprit was entirely internal: delayed scale-ups at Hopewell, Calvert City restart issues, and weather disruptions severely impaired profitability. Consequently, management was forced to slash its FY26 Adjusted EBITDA guidance for the second consecutive quarter to a midpoint of $392.5M, implying a full-year contraction.
🐂 Bull Case
Personal Care sales grew 3% driven by double-digit gains in biofunctional actives. Life Sciences volumes continue to grow in pharma applications, proving demand durability.
Cash flow from operations surged to $50M from $9M a year ago. Ongoing Free Cash Flow flipped from negative $6M to positive $29M, driven by aggressive and deliberate inventory reductions.
🐻 Bear Case
Operational issues at Hopewell and Calvert City are bleeding cash and profitability. Hopewell's slower productivity ramp directly caused a $10M-$12M reduction in FY26 expected cost savings.
Specialty Additives Adjusted EBITDA cratered 38% YoY to $16M despite flat sales, reflecting severe margin compression from operational costs, lower pricing, and Middle East energy weakness.
⚖️ Verdict: 🔴
Bearish. While breaking the multi-quarter streak of revenue decline is a positive step, severe internal operational failures are destroying margin leverage. A second consecutive guidance cut severely damages confidence in the $60M optimization program.
Key Themes
Manufacturing Scale-up Woes at Hopewell
The $60M manufacturing optimization program has hit a major speed bump. Slower-than-anticipated productivity at the Hopewell HEC site has forced management to reduce FY26 savings expectations by $10-$12M. This, combined with Calvert City repair delays, directly drove the 9% YoY Adjusted EBITDA decline and the guidance cut.
Specialty Additives Margin Collapse
Despite flat sales YoY ($134M), Specialty Additives Adjusted EBITDA fell from $26M to $16M. This translates to an acute margin compression from 19.4% to 11.9%. The segment was hit by a perfect storm: lower pricing to hold share, Hopewell manufacturing costs, and Middle East conflict-driven energy market weakness.
Personal Care Leading Growth
Personal Care is the standout growth engine. Sales increased 3% to $150M, driven by double-digit growth in biofunctional actives and strong execution across skin, hair, and microbial protection. Adjusted EBITDA held mostly stable at $43M, representing a healthy 29% margin despite competitive pricing actions.
Intermediates Showing Trough Stability
Intermediates sales fell 5% to $35M, but profitability is reversing positively. Adjusted EBITDA grew from $2M to $5M YoY. This highlights disciplined operational actions and favorable raw material costs more than offsetting the Calvert City commercial impacts.
Pricing Actions Initiated to Combat Inflation
Management noted global cost increases driven by rising energy markets, raw materials, and logistics (largely related to Middle East geopolitical tensions). In response, the company has announced broad pricing actions. How much of this pricing will stick in a still-tepid macro environment remains a critical item to monitor.
Other KPIs
Accelerating significantly from $9M in the prior-year quarter. This improvement was driven heavily by disciplined working capital management and meaningful inventory reductions, demonstrating management's focus on cash generation amid profitability struggles.
Decelerating from 32.6% in 25Q2. While sales were flat at $172M and pharma volumes grew, higher operational costs—specifically an estimated $5M hit from the Calvert City delay and weather—dragged down margins.
Guidance
Stable/Reversing. This implies roughly 1.5% growth over FY25's $1,824 million at the midpoint. This reflects resilient consumer end markets offsetting Middle East weakness and planned portfolio shifts away from construction.
Decelerating. Lowered from the previous $400-$420 million range. The $392.5 million midpoint implies a 2.1% contraction versus FY25's $401 million. This explicitly accounts for the slower productivity ramp at Hopewell and temporary weather/outage hits.
Stable. At the updated midpoint, this implies approximately $196 million in ongoing FCF, assuming the planned capital expenditures remain at roughly $100 million.
Key Questions
Hopewell Timeline and Visibility
You cited 'slower than anticipated productivity' at Hopewell causing a $10M-$12M hit to FY26 savings. What is the precise operational bottleneck, and what leading indicators prove this issue will not leak into FY27 estimates?
Specialty Additives Pricing Dynamics
Specialty Additives EBITDA fell 38% YoY. How much of this compression is temporary (Hopewell/weather) versus structural (pricing declines to capture share against Asian imports)?
Pricing Power Implementation
You announced pricing actions to address rising energy and logistics costs. Given the muted volume environment and competitive pressures highlighted in earlier quarters, what is your realistic expectation for price realization across the portfolio?